Mosseri Marlio Charles's Form 4 filing
Nuvectis Pharma, Inc.NVCT · filed Jul 24, 2023
- Accession no.
- 0001104659-23-083470
- Filed
- Jul 24, 2023
- Trade date
- Jul 20-21, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $119.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mosseri Marlio CharlesCIK 0001806384 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 20, 2023 | Common Stock | PPurchaseAcquired | +5,394 | $14.40F1 | +$77,673.6 | 2,577,156 | Direct | |
| Jul 21, 2023 | Common Stock | PPurchaseAcquired | +2,844 | $14.61 | +$41,550.84 | 2,580,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.10 to $14.42. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.